Skip Navigation



Hum. Reprod. Advance Access published online on August 27, 2004
Human Reproduction, doi:10.1093/humrep/deh357
© 2004 by European Society of Human Reproduction and Embryology
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/10/2206    most recent
deh357v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Huirne, J. A.F.
Right arrow Articles by Lambalk, C. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huirne, J. A.F.
Right arrow Articles by Lambalk, C. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received February 5, 2004
Accepted May 14, 2004

Article

Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels

Judith A.F. Huirne 1, Andre C.D. van Loenen 1, Roel Schats 1, Joseph McDonnell 1, Peter G.A. Hompes 1, Joop Schoemaker 1, Roy Homburg 1, Cornelis B. Lambalk 1*

1 Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Vrije Universiteit medical centre (VUmc), Amsterdam, The Netherlands

* To whom correspondence should be addressed. E-mail: cb.Lambalk{at}vumc.nl.


  Abstract

BACKGROUND: The aim of this study was to define the minimal effective dose of antide (Iturelix) to prevent premature luteinizing hormone (LH) surges in in vitro fertilization (IVF) patients. METHODS: In a prospective, single centre study, 144 IVF/ICSI patients were stimulated with r-hFSH from cycle day 2 and from cycle day 6 onwards, cotreated with daily 2 mg/2 ml (n=30), 1 mg/ml (n=30), 0.5 mg/ml (n=31), 0.5 mg/0.5 ml (n=23) and 0.25 mg/ml (n=30) GnRH antagonist (antide). Serum samples were taken three times daily during antide administration to assess antide and hormone levels. The minimal effective dose was defined as the lowest dose group with <2 LH surges (LH >12.4 IU/l and progesterone >2 ng/ml). RESULTS: Serum antide levels, mean LH and E2 levels per day and their area under the curves were dose-related to antide. The bioavailability of antide almost doubled after dilution in larger volumes. Pre-injection LH levels gradually increased during GnRH antagonist treatment. LH surges occurred in the lowest dose groups 0.5 mg/ml (3.2%), 0.5 mg/0.5 ml (6.7%) and 0.25 mg/ml (13.3%). Hence, 0.5 mg/ml is considered to be the minimal effective dose. Antide was overall well tolerated and safe. CONCLUSIONS: 0.5 mg/ml antide is the minimal effective dose to prevent an untimely LH surge in IVF patients stimulated with r-hFSH.

Keywords: antide; dose-finding; GnRH antagonist; IVF; LH.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
J.A. Huirne, R. Homburg, and C.B. Lambalk
Are GnRH antagonists comparable to agonists for use in IVF?
Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. H. Thomas, E. E. Telfer, and H. M. Fraser
Expression of Anti-Mullerian Hormone Protein during Early Follicular Development in the Primate Ovary in Vivo Is Influenced by Suppression of Gonadotropin Secretion and Inhibition of Vascular Endothelial Growth Factor
Endocrinology, May 1, 2007; 148(5): 2273 - 2281.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
C. B. Lambalk and R. Homburg
GnRH agonist for luteal support in IVF? Setting the balance between enthusiasm and caution
Hum. Reprod., October 1, 2006; 21(10): 2580 - 2582.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
J.A. Huirne, J.N. Hugues, C. Pirard, F. Fischl, J.C. Sage, J.L. Pouly, A. Obruca, D.M. Braat, A.C.D. van Loenen, and C.B. Lambalk
Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study
Hum. Reprod., June 1, 2006; 21(6): 1408 - 1415.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. A.F. Huirne, A. C.D. van Loenen, R. Schats, J. McDonnell, P. G.A. Hompes, J. Schoemaker, R. Homburg, and C. B. Lambalk
Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy
Hum. Reprod., February 1, 2005; 20(2): 359 - 367.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.